Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053079 | 0.83 | AURKA (0.67) | AURKASMN1; SMN2 | |
| SCHEMBL4059384 | 0.82 | AURKA (0.55) | AURKATRPV1SMN1; SMN2PRMT5KCNH2 | |
| SCHEMBL4060567 | 0.81 | AURKA (0.68) | AURKASMN1; SMN2PTGDR2KIF11GUSB | |
| SCHEMBL4053781 | 0.80 | SMN1; SMN2 (0.49) | AURKASMN1; SMN2 | |
| SCHEMBL13607765 | 0.80 | TRPV1 (0.49) | TRPV1CHEK2SCN1AKCNH2SCN5A | |
| SCHEMBL4055069 | 0.79 | SCD (0.56) | AURKATRPV1BRAF | |
| SCHEMBL4059854 | 0.79 | AURKA (0.51) | AURKATRPV1CHEK2PRMT5KCNH2 | |
| SCHEMBL4053038 | 0.78 | AURKA (0.49) | AURKATRPV1SMN1; SMN2CHEK2PRMT5 | |
| SCHEMBL4053465 | 0.78 | IKBKE (0.49) | AURKATRPV1BRAFCHEK2PRMT5 | |
| SCHEMBL1667430 | 0.78 | AURKA (0.68) | AURKASMN1; SMN2PTGDR2KIF11PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | AURKA 247/4885TRPV1 2690/4885SMN1; SMN2 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.